Efficacy, immunogenicity, and evidence for best-timing of pneumococcal vaccination in splenectomized adults: a systematic review

References

• Tahir F, Ahmed J, Malik F. Post-splenectomy sepsis: a review of the literature. Cureus. 2020;12:6–19.
   Web of Science ®Google Scholar
• Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin Microbiol Infect. 2001;7(12):657–660. Available from.
   PubMed Web of Science ®Google Scholar
• Sinwar PD. Overwhelming post splenectomy infection syndrome - Review study. Int J Surg. 2014;12(12):1314–1316. Available from.
   PubMed Web of Science ®Google Scholar
• Casciani F, Trudeau MT, Vollmer CM. Perioperative immunization for splenectomy and the surgeon’s responsibility: a review. JAMA Surg. 2020;155(11):1068–1077.
   PubMed Web of Science ®Google Scholar
• Okabayashi T, Hanazaki K. Overwhelming postsplenectomy infection syndrome in adults - A clinically preventable disease. World J Gastroenterol. 2008;14(2):176–179.
   PubMed Web of Science ®Google Scholar
• Luu S, Spelman D, Woolley IJ. Post-splenectomy sepsis: preventative strategies, challenges, and solutions. Infect Drug Resist. Sep 2019;12:2839–2851.
   PubMed Web of Science ®Google Scholar
• De Roux A, Schmöele-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46(7):1015–1023.
   PubMed Web of Science ®Google Scholar
• Kaijser B. Pneumococcal infections and the possible need for a vaccine. Scand J Infect Dis. 1979;11(3):179–184.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep. 2010. 59(9):253–257. Available from http://www.ncbi.nlm.nih.gov/pubmed/20224541
   PubMedGoogle Scholar
• De Carvalho Gomes H, Muscat M, Monnet DL, et al. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill. 2009;14:1–6. Available from.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at. www.covidence.org
   Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:14898.
   Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
   PubMed Web of Science ®Google Scholar
• McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55–61. Available from.
   PubMed Web of Science ®Google Scholar
• Landgren O, Björkholm M, Konradsen HB, et al. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin’s lymphoma. J Intern Med. 2004;255(6):664–673.
   PubMed Web of Science ®Google Scholar
• Cherif H, Landgren O, Konradsen HB, et al. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine. 2006;24(1):75–81.
   PubMed Web of Science ®Google Scholar
• Eigenberger K, Sillaber C, Greitbauer M, et al. Antibody responses to pneumococcal and hemophilus vaccinations in splenectomized patients with hematological malignancies or trauma. Wien Klin Wochenschr. 2007;119(7–8):228–234.
   PubMed Web of Science ®Google Scholar
• Wasserstrom H, Bussel J, Lim -LC-L, et al. Memory B cells and pneumococcal antibody after splenectomy. J Immunol. 2008;181(5):3684–3689.
   PubMed Web of Science ®Google Scholar
• Stanford E, Print F, Falconer M, et al. Immune response to pneumococcal conjugate vaccination in asplenic individuals. Hum Vaccin. 2009;5(2):85–91.
   PubMed Web of Science ®Google Scholar
• Langley JM, Dodds L, Fell D, et al. Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990-2002. BMC Infect Dis. 2010;10(1):219.
   PubMedGoogle Scholar
• Jahromi AS, Farjam MR, Makarem A, et al. Immunity to pneumococcal vaccine in splenectomized β-thalassemia patients. Am J Immunol. 2012;8(2):33–37.
   Google Scholar
• Forstner C, Plefka S, Tobudic S, et al. Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients. Vaccine. 2012;30(37):5449–5452. Available from.
   PubMed Web of Science ®Google Scholar
• Llupià A, Vilella A, Costas L, et al. Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted? Vaccine. 2012;30(13):2382–2386.
   PubMed Web of Science ®Google Scholar
• Rosado MM, Gesualdo F, Marcellini V, et al. Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: tailoring better vaccination strategies. Eur J Immunol. 2013;43(10):2659–2670.
   PubMed Web of Science ®Google Scholar
• Papadatou I, Piperi C, Alexandraki K, et al. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2014;59(6):862–865.
   PubMed Web of Science ®Google Scholar
• Papadatou I, Orthopoulos G, Theodoridou M, et al. Long-lasting hyporesponsivenss induced by the 23-valent pneumococcal polysaccharide vaccine (PPV23) in asplenic patients with β-thalassemia major. Vaccine. 2015;33(32):3779–3783.
   PubMed Web of Science ®Google Scholar
• Nived P, Jørgensen CS, Settergren B. Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals. Vaccine. 2015;33(14):1688–1694. Available from.
   PubMed Web of Science ®Google Scholar
• Karasartova D, Gazi U, Tosun O, et al. Anti-pneumococcal vaccine-induced cellular immune responses in post-traumatic splenectomized individuals. J Clin Immunol. 2017;37(4):388–396.
   PubMed Web of Science ®Google Scholar
• Olender A, Małkińska K, Roliński J, et al. Assessment of postvaccine immunity against streptococcus pneumoniae in patients with asplenia, including an analysis of its impact on bacterial flora of the upper respiratory tract and incidence of infections. J Immunol Res. 2018;2018:1691347.
   PubMed Web of Science ®Google Scholar
• Gazi U, Karasartova D, Sahiner IT, et al. The effect of splenectomy on the levels of PCV-13-induced memory B- and T cells. Int J Clin Pract. 2018;72(5):1–7.
   Web of Science ®Google Scholar
• Papadatou I, Lagousi T, Kattamis A, et al. Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with β-thalassemia: assessing the need for booster. Ann Hematol. 2019;98(3):775–779.
   PubMed Web of Science ®Google Scholar
• Shatz DV, Romero-Steiner S, Elie CM, et al., Antibody responses in postsplenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively. J Trauma. 53(6): 1037–1042. 2002.
   PubMedGoogle Scholar
• Orthopoulos GV, Theodoridou MC, Ladis VA, et al. The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with β-thalassemia. Vaccine. 2009;27(3):350–354.
   PubMed Web of Science ®Google Scholar
• Rezai MS, Ghaffari J, Mahdavi M, et al. Conjugate and 23-valent pneumococcal polysaccharide booster vaccination in asplenic patients with thalassemia major: a randomized clinical trial study. Casp J Intern Med. 2017;8. 16–22.
   PubMed Web of Science ®Google Scholar
• Sari TT, Akib AAP, Gatot D, et al. Pneumococcal vaccination for splenectomized patients with thalassemia major in Indonesia. Vaccine. 2017;35(35):4583–4586. Available from.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7(9):597–606.
   PubMed Web of Science ®Google Scholar
• Van Werkhoven CH, Huijts SM, Bolkenbaas M, et al. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin Infect Dis. 2015;61(12):1835–1838.
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999;29(2):281–288.
   PubMed Web of Science ®Google Scholar
• Bonanni P, Grazzini M, Niccolai G, et al. Recommended vaccinations for asplenic and hyposplenic adult patients. Hum Vaccines Immunother. 2017;13(2):359–368.
   PubMed Web of Science ®Google Scholar